R&D | Cutting-edge science and innovative research

News

GLP-1 drugs linked to reduced acute schizophrenia episodes

The list of illnesses that may benefit from treatment with GLP-1 drugs gets ever longer, and a study has found that schizophrenia may be an addition.

News

Could OMass become the UK's 'big biotech' company?

UK-based OMass Therapeutics' ambition to join the 'big biotech' ranks has been bolstered by an impressive $310m third-round financing.

R&D

clinical trial recruitment patient enrolment checklist

Why clinical trials lose a quarter of their patients before ...

Data fragmentation creates unnecessary burden on sponsors and the people clinical trials aim to serve.

R&D

Sponsored

Beyond recruitment: Creating patient engagement that lasts

In the fourth episode of the IQVIA-sponsored PSCS leadership video series, Zoltan Varga discusses the importance of understanding patient motivations

News

GSK planning 1,200 job cuts in Belgium, says paper

GSK is said to be preparing to cut around 1,200 positions from its workforce in Belgium as part of a cost-saving programme launched by CEO Luke Miels.

News

UK Vaccine Taskforce head lifts lid on Novavax deal

The UK’s unique offering as a life sciences research hub helped convince US biotech Novavax to develop its COVID-19 jab there, according to the head of the country’s Vaccines Taskforce.&nbs

News

Activist investor Elliott builds stake in GSK after fresh tr...

Activist investor Elliott Management has built a significant stake in GlaxoSmithKline, after a poor run of clinical trial results this year raised questions about management’s strategy to t

News

Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms.

Magic mushroom compound matches antidepressant in clinical t...

The active compound in magic mushrooms – psilocybin – seems to be at least as effective as a commercially-available antidepressant in a phase 2 trial, and may work more quickly.

Debates & Insights

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Sponsored

Synthetic control arms in clinical trials: Making it happen

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials.

R&D

Sponsored

How synthetic control arms are changing clinical trials

Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change. With drawn-out timelines and billions

News

GLP-1 drugs linked to reduced acute schizophrenia episodes

The list of illnesses that may benefit from treatment with GLP-1 drugs gets ever longer, and a study has found that schizophrenia may be an addition.

News

Could OMass become the UK's 'big biotech' company?

UK-based OMass Therapeutics' ambition to join the 'big biotech' ranks has been bolstered by an impressive $310m third-round financing.

Press Releases

Media Partner

PHARMAP 2027 Addresses the Future of Pharmaceutical Manufact...

Senior pharma professionals gather in Berlin on 19-20 April for the Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2027

Press Releases

Partner Content

The Evolution Summit Announces September 2026 Program for Cl...

Marcus Evans announces The Evolution Summit, taking place September 28-29, 2026 at Park Hyatt Aviara Resort, Golf Club & Spa, San Diego, CA.

Views & Analysis

R&D

Why clinical trials lose a quarter of their patients before ...

Data fragmentation creates unnecessary burden on sponsors and the people clinical trials aim to serve.

R&D

Sponsored

Beyond recruitment: Creating patient engagement that lasts

In the fourth episode of the IQVIA-sponsored PSCS leadership video series, Zoltan Varga discusses the importance of understanding patient motivations

R&D

Clinical Trials Round-Up: July/August 2026

While the volume of announcements hit a mid-year slump, July and August still produced an exciting array of updates across the drug development arena.

Deep Dive

R&D

Cancer misinformation is a trust problem, not just an inform...

R&D

The GLP-1 Reckoning

R&D

Designing obesity trials around real lives: How patient cent...

R&D

From obesity to outcomes abstract visual

Sponsored

The future of cardiometabolic trials: From obesity to outcom...

Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO

R&D

Sponsored

Exploring the future: Opportunities and challenges in cell a...

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

R&D

Sponsored

Beyond clinical: Boosting recruitment and retention with SDO...

The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.

Podcasts

R&D

pharmaphorum podcast Episode 278, Shai Melcer, IIA

Bioconvergence & future human health, with Shai Melcer

Shai Melcer discusses bioconvergence, a multidisciplinary research and development approach that merges technologies.

R&D

pharmaphorum podcast Episode 272, Dr Harpreet Singh, Precision for Medicine

Understanding Operation Trialblazer, with Dr Harpreet Singh

Dr Harpreet Singh, CMO at Precision for Medicine, brings both an insider and outsider perspective to discussing Operation TRIALBLAZER.

R&D

Prevent-Stop-Cure: Diagnostics & chronic liver disease, with...

Video

R&D

Sponsored

Beyond recruitment: Creating patient engagement that lasts

In the fourth episode of the IQVIA-sponsored PSCS leadership video series, Zoltan Varga discusses the importance of understanding patient motivations

R&D

LSX 2026 with Sam Possemiers, MRM Health

Taking the microbiome seriously, with Sam Possemiers

pharmaphorum catches up with MRM Health founder and CEO Sam Possemiers at LSX 2026.

R&D

Sponsored

Turning recruitment potential into enrolment reality

In the fourth episode of the IQVIA-sponsored PSCS leadership video series, Karen Townsend, senior director of medical affairs discusses SEELs

White Papers

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

R&D

Sponsored

A data-driven guide to small molecule drug discovery and dev...

A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.

R&D

A man stood on a rock looking towards the horizon

Sponsored

A New Framework to Engineer Breakthrough Value for Medicines

A new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’.